Arrowhead Pharmaceuticals Q3 2026 Earnings Report

Arrowhead Pharmaceuticals EPS Results

• Actual EPS: N/A
• Consensus EPS: -$1.28
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Arrowhead Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $44.17 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Arrowhead Pharmaceuticals Announcement Details

• Quarter: Q3 2026
• Date: 8/4/2026
• Time: After Market Closes
• Conference Call Date: Tuesday, August 4, 2026
• Conference Call Time: 4:30PM ET

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development. Lead programs target chronic hepatitis B virus (HBV) infection (ARO-HBV), alpha-1 antitrypsin deficiency (ARO-AAT), cardiovascular disease through the silencing of apolipoprotein C-III (ARO-APOC3), and pulmonary diseases such as cystic fibrosis (ARO-ENaC). Arrowhead has entered collaboration agreements and licensing partnerships with major global pharmaceutical firms to accelerate the development and potential commercialization of its RNAi candidates.

Arrowhead conducts its research and early clinical studies primarily in the United States, with clinical trial sites and regulatory interactions spanning North America, Europe and Asia. The company’s manufacturing strategy combines internal capabilities with external contract development and manufacturing organizations (CDMOs) to support both preclinical work and advancing clinical-stage assets. This hybrid model is designed to optimize scalability as programs progress toward late-stage clinical testing.

Headquartered in Pasadena, California, Arrowhead is led by Chief Executive Officer Christopher Anzalone, who has guided the company through multiple platform refinements and strategic partnerships. The executive team comprises experienced drug developers and industry veterans dedicated to harnessing RNAi to address unmet medical needs. Arrowhead continues to expand its research collaborations and invest in next-generation delivery technologies to broaden its therapeutic reach.